John L. Villano

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Michael Weller, Nicholas Butowski, David Tran et al. · The Lancet Oncology · 2017 · 1.1K citations

Medicine, Oncology, Pharmacology +13

NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality

Roger Stupp, Eric T. Wong, Andrew A. Kanner et al. · European Journal of Cancer · 2012 · 847 citations

Medicine, Neurosurgery, Oncology +14

Age, gender, and racial differences in incidence and survival in primary CNS lymphoma

John L. Villano, Matthew Koshy, Habib Shaikh et al. · British Journal of Cancer · 2011 · 562 citations · Full text

Medicine, Biostatistics, Oncology +15

First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma

Linda M. Liau, Keyoumars Ashkan, David D. Tran et al. · Journal of Translational Medicine · 2018 · 540 citations · Full text

Medicine, Immunology, Oncology +17

Improved survival time trends for glioblastoma using the SEER 17 population-based registries

Matthew Koshy, John L. Villano, Therese A. Dolecek et al. · Journal of Neuro-Oncology · 2011 · 478 citations · Full text

Medicine, Biostatistics, Oncology +16